Is Aurinia Pharmaceuticals (AUPH) Outperforming Other Medical Stocks This Year?
Here is how Aurinia Pharmaceuticals (AUPH) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?
Here is how Aurinia Pharmaceuticals (AUPH) and Cardinal Health (CAH) have performed compared to their sector so far this year.
What Makes Aurinia Pharmaceuticals (AUPH) a Strong Momentum Stock: Buy Now?
Does Aurinia Pharmaceuticals (AUPH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year?
Here is how Aurinia Pharmaceuticals (AUPH) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Can Aurinia (AUPH) Run Higher on Rising Earnings Estimates?
Aurinia Pharmaceuticals (AUPH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Aurinia Pharmaceuticals (AUPH) Surpasses Q3 Earnings and Revenue Estimates
Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.1 per share a year ago.
Aurinia Pharma: The Easiest Money May Have Been Made (Rating Downgrade)
Aurinia Pharmaceuticals Inc. reported total revenues of $70M in Q2 '25, aided by record Lupkynis net product sales of $66.6M. AUPH management continues to execute well, maintaining positive cash flow, but faces the risk of having only one revenue-generating drug. AUR200 doesn't appear to be worthless; instead, it could have the potential to compete with other compounds in the same class, although it isn't first-in-class.
Aurinia (AUPH) Upgraded to Buy: Here's What You Should Know
Aurinia (AUPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aurinia Pharmaceuticals Inc. (AUPH) Q2 2025 Earnings Call Transcript
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Gregory F. Keenan - Chief Medical Officer Joseph M.
Aurinia Pharmaceuticals (AUPH) Q2 Earnings Miss Estimates
Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.16 per share, missing the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.02 per share a year ago.
The Play On Aurinia Pharmaceuticals: Rising Cash Flow Provides Opportunity
I revisit biopharma name Aurinia Pharmaceuticals Inc. for the first time in 2025 after the company reported solid Q1 results in May. The quarter saw Lupkynis net product revenues up 25% year-over-year to $60 million and management reaffirm FY2025 guidance. The company has a strong balance sheet, a free cash flow turnaround, and projected profit growth to $0.59/share in FY2025 to support a positive investment outlook.
Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains?
Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
